Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial

被引：0

作者：

Eyerich, Kilian ^{[1
]}

Gottlieb, Alice B. ^{[2
]}

Piaserico, Stefano ^{[3
]}

Beissert, Stefan ^{[4
]}

Gooderham, Melinda ^{[5
,6
]}

Kirby, Brian ^{[7
]}

Tilt, Nicola ^{[8
]}

Madden, Cynthia ^{[9
]}

Wiegratz, Susanne ^{[10
]}

de Cuyper, Dirk ^{[11
]}

Elewski, Boni ^{[12
]}

机构：

[1] Univ Freiburg, Dept Dermatol, Med Ctr, Freiburg, Germany

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[3] Univ Padua, Dept Med, Dermatol Unit, Padua, Italy

[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany

[5] Prob Med Res, SKiN Ctr Dermatol, Peterborough, ON, Canada

[6] Queens Univ, Kingston, ON, Canada

[7] Univ Coll Dublin, St Vincents Univ Hosp, Elm Pk & Charles Inst, Dublin, Ireland

[8] UCB Pharma, Slough, Berks, England

[9] UCB Pharma, Morrisville, NC USA

[10] UCB Pharma, Monheim, Germany

[11] UCB Pharma, Brussels, Belgium

[12] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43878

引用

页码：AB22 / AB22

页数：1

共 50 条

[1] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Merola, Joseph F.
Elewski, Boni
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
[2] Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
Shumack, Stephen
Blauvelt, Andrew
Iversen, Lars
McBride, Sandy
Gooderham, Melinda
Staubach-Renz, Petra
Yamauchi, Paul
Staelens, Fabienne
Vanvoorden, Veerle
White, Katy
Gisondi, Paolo
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 17 - 18
[3] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Lebwohl, Mark
Ghoreschi, Kamran
Strober, Bruce
Eyerich, Kilian
Cather, Jennifer
Wang, Maggie
Cioffi, Christopher
Deherder, Delphine
Staelens, Fabienne
Gomez, Natalie Nunez
Puig, Luis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
[4] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Eyerich, Kilian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
[5] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Spelman, Lynda
Eyerich, Kilian
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
[6] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
Kern, Johannes S.
Feldman, Steven R.
Gottlieb, Alice B.
Soung, Jennifer
Augustin, Matthias
Gisondi, Paolo
Peterson, Luke
Vanvoorden, Veerle
Ciaravino, Valerie
Gomez, Natalie Nunez
Warren, Richard B.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
[7] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Feldman, Steven R.
Gottlieb, Alice B.
Soung, Jennifer
Augustin, Matthias
Gisondi, Paolo
Peterson, Luke
Vanvoorden, Veerle
Ciaravino, Valerie
Gomez, Natalie Nunez
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
[8] Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
Gottlieb, Alice B.
Langley, Richard G.
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
[9] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Puig, Luis
Lebwohl, Mark
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Gomez, Natalie Nunez
Eyerich, Kilian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
[10] Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48-144) of the BE RADIANT phase 3b trial
Strober, Bruce
Puig, Luis
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
Wang, Maggie
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Wiegratz, Susanne
Paul, Carle
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB21 - AB21

← 1 2 3 4 5 →